How have LIXTW shares performed in 2024?

Lixte Biotechnology's stock was trading at $0.0375 at the start of the year. Since then, LIXTW stock has increased by 44.0% and is now trading at $0.0540. View the best growth stocks for 2024 here .

Are investors shorting Lixte Biotechnology?

Lixte Biotechnology saw a increase in short interest in April. As of April 15th, there was short interest totaling 500 shares, an increase of 150.0% from the March 31st total of 200 shares. Based on an average trading volume of 3,000 shares, the days-to-cover ratio is currently 0.2 days. View Lixte Biotechnology's Short Interest .

How do I buy shares of Lixte Biotechnology?

Shares of LIXTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LIXTW

Lixte Biotechnology (LIXTW) Stock Price, News & Analysis

→ Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad)

Free LIXTW Stock Alerts

$0.05

0.00 (0.00%)

(As of 05/7/2024 ET)

Compare

Today's Range: $0.05
▼
$0.05
50-Day Range: $0.04
▼
$0.11
52-Week Range: $0.03
▼
$0.14

Volume: 4,640 shs
Average Volume: 4,599 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get Lixte Biotechnology alerts:

Ad Crypto 101 Media

Tech GIANT’s Plans to Revolutionize Crypto…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Lixte Biotechnology Stock (NASDAQ:LIXTW)

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

LIXTW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LIXTW Stock News Headlines

March 27, 2024 | finance.yahoo.com

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

February 27, 2024 | finance.yahoo.com

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research

May 7, 2024 | Porter & Company (Ad)

Obama’s Forever Term [exposed]

America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.

February 26, 2024 | finanznachrichten.de

Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

February 1, 2024 | uk.investing.com

Lixte Biotechnology Holdings Inc (LIXT)

October 9, 2023 | finance.yahoo.com

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

September 26, 2023 | finanznachrichten.de

Lixte Biotechnology Holdings, Inc.: LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

September 20, 2023 | finance.yahoo.com

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

See More Headlines

Receive LIXTW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:LIXTW
CUSIP: N/A
CIK: 1335105
Web: N/A
Phone: 631-830-7092
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Bastiaan van der Baan M.Sc. (Age 52)
President, CEO & Chairman of the Board of Directors
Comp: $172.78k
Mr. Robert Neal Weingarten (Age 72)
VP & CFO
Comp: $175k
Mr. Eric J. Forman J.D. (Age 45)
VP & COO
Comp: $200k
Dr. James S. Miser M.D. (Age 77)
Chief Medical Officer
Comp: $175k

Key Competitors

View All Competitors

LIXTW Stock Analysis - Frequently Asked Questions

How have LIXTW shares performed in 2024?: Lixte Biotechnology's stock was trading at $0.0375 at the start of the year. Since then, LIXTW stock has increased by 44.0% and is now trading at $0.0540.
View the best growth stocks for 2024 here.
Are investors shorting Lixte Biotechnology?: Lixte Biotechnology saw a increase in short interest in April. As of April 15th, there was short interest totaling 500 shares, an increase of 150.0% from the March 31st total of 200 shares. Based on an average trading volume of 3,000 shares, the days-to-cover ratio is currently 0.2 days.
View Lixte Biotechnology's Short Interest.
How do I buy shares of Lixte Biotechnology?: Shares of LIXTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIXTW) was last updated on 5/7/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial